Rifampin Does Not Improve the Efficacy of Quinolone Antibacterial Prophylaxis in Neutropenic Cancer Patients: Results of a Randomized Clinical Trial
- 10 May 2000
- journal article
- clinical trial
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 18 (10) , 2126-2134
Abstract
PURPOSE: To determine whether the addition of rifampin to a quinolone-based antibacterial prophylactic regimen in patients undergoing high-dose chemotherapy (HDC) with peripheral-blood stem-cell transplantation (PBSCT) decreases the incidence of neutropenia and fever, Gram-positive bacteremia, and infection-related morbidity. PATIENTS AND METHODS: Patients with solid tumors undergoing HDC with PBSCT were randomized to receive prophylactic antibiotics with either ciprofloxacin 500 mg orally every 8 hours or the same ciprofloxacin regimen with rifampin 300 mg orally every 12 hours. Prophylaxis was started 48 hours before stem-cell reinfusion. Patients were monitored to document the occurrence of neutropenia and fever, incidence and cause of bacterial infection, time to onset and duration of fever, requirement for intravenous antimicrobials, and length of hospital admission. RESULTS: Sixty-five patients were randomized to receive ciprofloxacin and 65 to receive ciprofloxacin plus rifampin, and from these groups, 62 and 61 were assessable, respectively. The proportion of patients who developed neutropenia and fever was 87% in the group treated with ciprofloxacin and 78% in the group treated with ciprofloxacin and rifampin (P = .25). Although there was a trend toward a reduction in the overall incidence of bacteremia (12 v 4 patients), and Gram-positive bacteremia (8 v 2 patients) with the addition of rifampin, none of these comparisons was statistically significant (P = .05 and P = .09, respectively). CONCLUSION: The results of this study, which demonstrate that rifampin does not improve ciprofloxacin antibacterial prophylaxis in cancer patients undergoing HDC with PBSCT support but that it does increase the occurrence of undesirable side effects, do not support the routine use of rifampin in this setting.Keywords
This publication has 35 references indexed in Scilit:
- Efficacy of quinolone prophylaxis in neutropenic cancer patients: a meta-analysis.Journal of Clinical Oncology, 1998
- Granulocyte colony-stimulating factor following peripheral-blood progenitor-cell transplant in non-Hodgkin's lymphoma.Journal of Clinical Oncology, 1995
- Randomized study of growth factors post-peripheral-blood stem-cell transplant: neutrophil recovery is improved with modest clinical benefit.Journal of Clinical Oncology, 1994
- The new fluorinated quinolones for antimicrobial prophylaxis in neutropenic cancer patientsEuropean Journal of Cancer, 1993
- Streptococcal and Enterococcal Bacteremia in Patients with CancerClinical Infectious Diseases, 1992
- PROPHYLAXIS OF BACTERIAL INFECTIONS WITH CIPROFLOXACIN IN PATIENTS UNDERGOING BONE MARROW TRANSPLANTATIONTransplantation, 1991
- Oral Norfloxacin for Prevention of Gram-Negative Bacterial Infections in Patients with Acute Leukemia and GranulocytopeniaAnnals of Internal Medicine, 1987
- Protective isolation and antimicrobial decontamination in patients with high susceptibility to infectionInfection, 1978
- ORAL NON-ABSORBED ANTIBIOTICS PREVENT INFECTION IN ACUTE NON-LYMPHOBLASTIC LEUKqMIAThe Lancet, 1977
- Protected Environments and Prophylactic AntibioticsNew England Journal of Medicine, 1973